Journal of Pharmaceutical Investigation

  • 제39권6호
  • /
  • Pages.401-409
  • /
  • 2009
  • /
  • 2093-5552(pISSN)
  • /
  • 2093-6214(eISSN)
한국약제학회 (The Korean Society of Pharmaceutical Sciences and Technology)
권호 표지
DOI QR코드

DOI QR Code

비글견을 이용한 케토롤락트로메타민 서방형 펠렛 제제의 위궤양 증상 비교와 약물속도론적 평가

Pharmacokinetic Evaluation and Gastric Ulcer Symptoms comparison of Ketorolac Tromethamine Sustained-Release Pellets after Oral Administration in Beagle Dogs

  • 윤양노 (성균관대학교 약학대학,한국화학연구원 바이오소재연구센터) ;
  • 김수지 (충남대학교 약학대학,한국화학연구원 바이오소재연구센터) ;
  • 정석현 (한국화학연구원 바이오소재연구센터) ;
  • 김효정 (한국화학연구원 바이오소재연구센터) ;
  • 박은석 (성균관대학교 약학대학) ;
  • 황성주 (충남대학교 약학대학) ;
  • 이영원 (충남대학교 수의과대학) ;
  • 성하수 (한국화학연구원 바이오소재연구센터) ;
  • 신병철 (한국화학연구원 바이오소재연구센터) ;
  • 조선행 (한국화학연구원 바이오소재연구센터)
  • Yoon, Yang-No (College of Pharmacy, Sungkyunkwan University,Korea Research Institute of Chemical Technology Biomaterial Research Center) ;
  • Kim, Su-Ji (College of Pharmacy, Chungnam National University,Korea Research Institute of Chemical Technology Biomaterial Research Center) ;
  • Jung, Suk-Hyun (Korea Research Institute of Chemical Technology Biomaterial Research Center) ;
  • Kim, Hyo-Jeong (Korea Research Institute of Chemical Technology Biomaterial Research Center) ;
  • Park, Eun-Seok (College of Pharmacy, Sungkyunkwan University) ;
  • Hwang, Sung-Joo (College of Pharmacy, Chungnam National University) ;
  • Lee, Yong-Won (College of Veterinary Medicine, Chungnam National University) ;
  • Seong, Ha-Soo (Korea Research Institute of Chemical Technology Biomaterial Research Center) ;
  • Shin, Byung-Cheol (Korea Research Institute of Chemical Technology Biomaterial Research Center) ;
  • Cho, Sun-Hang (Korea Research Institute of Chemical Technology Biomaterial Research Center)
  • 발행 : 2009.12.20
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Ketrorolac tromethamine (KT), a nonsteroidal anti-inflammatory drug (NSAID) is required repeated administration due to its short blood half-life. To avoid dose-dependent side effects of KT, sustained-release pellets containing KT were prepared by coating with Eudragit$^{(R)}$ RS 100 and Eudragit$^{(R)}$ NE 30D. The in vitro and in vivo drug release behavior of KT from Eudragit$^{(R)}$ RS 100 and NE 30D coated pellet (SR-A), Eudragit$^{(R)}$ RS 100 coated pellet (SR-B) and conventional commercial immediate-release tablet (IR) was investigated. KT from SR-A and SR-B was slowly released over several hours, whereas IR showed rapid initial release in vitro. The pharmacokinetic study in vivo was performed by oral administration in beagle dogs. 5 mg IR was administered 3 times at intervals 5 hr. Five milligrams of IR was administered 3 times at intervals of 5 hr and 15 mg of SR-A and SR-B did once. After administering IR, KT concentration in blood showed high peak- trough fluctuation and stomach ulcer were discovered. On the other hand, SR-A and SR-B sustainedly released KT and reduced the occurrence of stomach ulcer. There sustained-release pellets will be effective system to minimize dosedependent of side effect and improve patient compliance.

키워드

참고문헌

  1. P. Maden, Sustained release drug delivery system; Part I-an overview. Pharm Manuf., 2(1), 23 (1985)
  2. G.. Ballard, An overview of prolonged action drug dosage forms, in sustained and controlled release drug delivery system, (J.R. Robinson, ed), Marcel Dekker, Inc., 1-69 (1978)
  3. A. Rubinstein, V.H.K. Li, P. Gruber and J.R. Robinson, Gastrointestinal-physiological variables affecting the performance of oral sustained release dosage forms. Oral sustained release formulation ; design and formulation.,125-156 (1990).
  4. S.H Kwak and S.J hwang, Pharmacokinetic Evaluation of ketorolac Tromethamine Sustained-Release Pellets after Oral Administration in Rabbits, J. Kor. Pharm. Sci., 30(4), 241-246 (2000)
  5. M.S Gordon, T.L. Ling and J.P. Yee, Ketorolac tromethamine bioavailability via tablet, capsule, and oral solution dosage forms, Drug Dev. Ind. Pharm., 21, 1143-1115 (1995) https://doi.org/10.3109/03639049509026664
  6. M. Brandl, D. Conley and D. Johnsom, Racemization of ketrotolac in aqueous solution, J. Pharm. Sci., 84, 1045-1048 (1995) https://doi.org/10.1002/jps.2600840903
  7. M. Brandl, A. Magill, V. Rudraraju and M.S. Gordon, Approaches for improving the stability of ketorolac in power blends, J. Pharm. Sci., 84, 1151-1153 (1995). https://doi.org/10.1002/jps.2600841003
  8. S.T. Borodkin and F.E. Tucker, Linear drug release from laminated hydroxypropylcellulose-polyvinyl acetate films. J. Pharm. Sci., 64, 1289-1293 (1975) https://doi.org/10.1002/jps.2600640806
  9. L. Gu, H.S. Chiang and A. Becker, Kinetics and mechanisms of the autoxidation of ketorolac tromethamine in aqueous solution. Int. J. Pharm., 41, 95-104 (1988) https://doi.org/10.1016/0378-5173(88)90141-X
  10. J.P. Yee, J.E. Koshiver, C. Allbon and C.R. Brown, Comparison of intramuscular ketorolac tromethamine and morphine sulfate for analgesia of pain after major surgery. Phamacotherapy., 6, 253-261 (1986). https://doi.org/10.1002/j.1875-9114.1986.tb03485.x
  11. D. Jung, E.J. Mroszczak, A. Wu, T.L. Ling, H. Sevelius and L. Bynum, Pharmacokinetics of ketorolac and p-hydroxyketorolac following oral and intramuscular administration of ketorolac tremethanmine, Pharm. Res., 6, 62-65 (1989) https://doi.org/10.1023/A:1015803803650
  12. M. Vakily, B. Corrigan and F. Jamali, The problem of racemization in the stereospecific assay and pharmacokinetic evaluation in ketorolac in human and rats, Pharm. Res., 12, 1652-1657 (1995) https://doi.org/10.1023/A:1016245101389
  13. L. Gu, H.S. Chiang and A. Becker, Kinetics and mechanisms of the autoxidation of ketorolac tromethamine in aqueous solution, Int. J. Pharm., 41, 95-104 (1988). https://doi.org/10.1016/0378-5173(88)90141-X
  14. R.C.C. Fu and D.M. Lidgate, In vitro rabbit corneal permeability study of ketorolac tromethamine, a nonsteroidal anti-inflammatory agent, Drug Dev. Ind. Pharm., 12, 2403-2430 (1986). https://doi.org/10.3109/03639048609063190
  15. D.M. Lidgate, R.C. Fu and J.S. Fleitman, Corneal permeability of ketorolac tromethamine when formulated with tobramycin, Drug Dev. Ind. Pharm., 15, 1779-1795 (1989). https://doi.org/10.3109/03639048909052401
  16. C. Madhu, P.J. Rix, M.J. Shackleton, T.G. Nguyen and D.D. Tang-Liu, Effect of benzalkonium chloride/EDTA on the ocular bioavailability of ketorolac tromethamine following ocular instillation to normal and de-epithelialized corneas of rabbits, J. Pharm. Sci., 85, 415-418 (1996). https://doi.org/10.1021/js9504189
  17. S.D. Roy and E. Manoukian, Permeability of ketorolac acid and its ester analogs (prodrug) through human cadaver skin, J. Pharm. Sci., 83, 1548-1553 (1994). https://doi.org/10.1002/jps.2600831106
  18. S.D. Roy, E. Manoukian and D. Combs, Absorption of transdermally delivered ketorolac acid in humans, J. Pharm. Sci., 84, 49-52 (1995). https://doi.org/10.1002/jps.2600840112
  19. S.D. Roy and E. Manoukian, Transdermal delivery of ketorolac tromethamine: permeation enhancement device design, and pharmacokinetics in healthy humans, J. Pharm. Sci., 84, 1190-1196 (1995). https://doi.org/10.1002/jps.2600841010
  20. J.A. Cordero, L. Alarcon, E. Escribano, R. Obach and J. Domenech, A comparative study of the transdermal penetration of a series of nonsteroidal anti-inflammatory drugs, J. Pharm. Sci., 86, 503-508 (1997). https://doi.org/10.1021/js950346l
  21. K. Devi and K.L. Paranjothy, Development and evaluation of free films and transdermal patches of ketorolac tromethamine using polymers and pressure sensitive adhesives, Eastern Pharmacist., 41, 97-100 (1998).
  22. R. Kamineni, R.A. Naresh and N. Udupa, ketorolac tromethamine: oral vs transdermal iontophoresis, plasma concentration- time profiles, Indian Drugs., 32, 50-52 (1995).
  23. K. Park, D. Verotta, S.K. Gupta and L.B. Sheiner, Passive versus electrotransport-facilitated transdermal absorption of ketorolac, Clinical Pharmacology & Therapeutics., 63, 303-315 (1998). https://doi.org/10.1016/S0009-9236(98)90162-X
  24. S.D. Roy, D.J. Chatterjee, E. Manoukian and A. Divor, Permeability of pure enantiomers of ketorolac through human cadaver skin, J. Pharm. Sci., 84, 987-990 (1995). https://doi.org/10.1002/jps.2600840815
  25. D.M. Brahmankar, R.M. Karwa and S.B. Jaiswal, Cellulose matrices for controlled release of ketorolac tromethamine, Indian Drugs., 33, 120-123 (1996).
  26. L. Genc, E. Guler and N. Hegazy, Film coated enteric tablet formulation of ketorolac tromethamine, Drug Dev. Ind. Pharm., 23, 1007-1011 (1997). https://doi.org/10.3109/03639049709149154
  27. B.A. Sathyamurthy, Formulation and evaluation of ketorolac tromethamine gels, Eastern Pharmacist., 41, 135-136 (1998).
  28. H. Zia, S.F. Rashed, M. Quadir, T.E. Needham and E. Squillante, ketorolac tromethamine and ketoprofen suppositories: release profiles and bioavailability of a cocoa butter base formula in rabbits, Int. J. Pharm. Compounding., 2, 390-393 (1998).
  29. D.K. Fuller and P.J. Kalekas, ketorolac and gastrointestinal ulceration, Ann. Pharmacother., 27, 978-979 (1993).
  30. J.E. Wiedrick, E.G. Friesen, A.M. Garton and N.H. Otten, Upper gastrointestinal bleeding associated with oral ketorolac therapy, Ann. Pharmacother., 28, 1109 (1994). https://doi.org/10.1177/106002809402800919
  31. M.A. Campanero, A. L pez-Oc riz, E. Garc a-Quetglas, B.S daba and J.R. Azanza, Determination of ketorolac enantiomers in plasma using enantioselective liquid chromatogtaphy: application to pharmacokinetic studies, Chromatographia., 48, 203-208 (1998). https://doi.org/10.1007/BF02467672
  32. U.K Jee and I.S. Cho, Preparation and evaluation of hydrogel of ketorolac for transdermal formulation, J. Kor. Pharm. Sci., 33(1), 21-28 (1999).
  33. J.S. Park, K.W. Nam, In Vitro Dissolution of Felodipine from Extended-Release Pellets, J. Kor. Pharm. Sci., 37(3), 193-196 (2007)